Uncovering the distinct dynamics of response to teclistamab treatment in HR-SMM versus R/R myeloma

Nayda Bidikian, MD, Dana-Farber Cancer Institute, Boston, MA, provides insight into the longitudinal single-cell immune profiling of patients with high-risk smoldering multiple myeloma (HR-SMM) or relapsed/refractory (R/R) multiple myeloma (MM) receiving teclistamab. Dr Bidikian discusses the significant differences in the immune composition of the peripheral blood observed at baseline between the groups and then highlights the distinct dynamics of response to teclistamab. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.